Brian Druker, M.D.

See Also

Website

Brian Druker, M.D.

Director, Knight Cancer Institute

OHSU Knight Cancer Institute

Dr. Druker specializes in caring for and treating patients with chronic myelogenous leukemia (CML). In his early medical training, witnessing chemotherapy's effects on patients drove him to find a better way to treat cancer. Starting in the lab, he led the development and clinical trials of the drug Gleevec for CML. Gleevec was the first of its kind – a highly successful daily oral medication to target damaged cells, leave healthy cells alone and cause minimal side effects. Dr. Druker continues to seek even better treatments for his patients, who are his inspiration. In 2009, Dr. Druker was honored with "America's Nobel Prize" in medicine, the Lasker-DeBakey Award for Clinical Medical Research.

As Director of the Knight Cancer Institute, a national leader in translational research, Dr. Druker and his team are focused on making unprecedented advances in cancer research with more than 1,000 research projects under way. More than 200 clinical trials are currently in progress, with the goal of transforming discoveries into new cures, standards of care, treatments and therapies.

He received his medical degree from the University of California San Diego, completed his residency at Barnes Hospital, Washington University, St. Louis and completed his fellowship in Medical Oncology at the Dana-Farber Cancer Institute, Harvard Medical School, Boston. 

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on December 13, 2011